Studies aflibercept 8 mg use in people with wet age-related macular degeneration
Observes how aflibercept 8 mg works in routine care for wet macular degeneration.
Plain-language title generated from the registry record
Registry title: Real-world Study of Aflibercept 8 mg in nAMD
Key facts
- Where
- Beijing, Chengdu, Dalian, Fuzhou, Harbin, Hohhot, Jinan, Nanyang, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi’an, and Zunyi, ChinaSee the 27 sites
Where in China
- Beijing Chao-Yang Hospital, Capital Medical UniversityBeijing, ChinaNot yet recruiting
- Beijing Friendship Hospital, Capital Medical UniversityBeijing, ChinaTaking people
- Beijing Haidian HospitalBeijing, ChinaTaking people
- Peking Union Medical College HospitalBeijing, ChinaNot yet recruiting
- Peking University First HospitalBeijing, ChinaNot yet recruiting
- Peking University People's HospitalBeijing, ChinaTaking people
- Peking University Third HospitalBeijing, ChinaNot yet recruiting
- Sichuan Academy of Medical Sciences sichuan Provincial People's HospitalChengdu, ChinaNot yet recruiting
- Dalian No.3 People'S HospitalDalian, ChinaTaking people
- The First Affiliated Hospital of Fujian Medical UniversityFuzhou, ChinaNot yet recruiting
- The 2nd Affiliated Hospital of Harbin Medical UniversityHarbin, ChinaNot yet recruiting
- The Affiliated Hospital of Inner Mongolia Medical UniversityHohhot, ChinaNot yet recruiting
- Jinan Second People's HospitalJinan, ChinaNot yet recruiting
- Nanyang Eye HospitalNanyang, ChinaTaking people
- Ningbo Eye HospitalNingbo, ChinaNot yet recruiting
- Qingdao Eye Hospital of Shandong First Medical UniversityQingdao, ChinaNot yet recruiting
- Shanghai Tenth People's HospitalShanghai, ChinaNot yet recruiting
- Tong Ren Hospital,Shanghai Jiao Tong University School Of MedicineShanghai, ChinaNot yet recruiting
- The Fourth People's Hospital of ShenyangShenyang, ChinaNot yet recruiting
- Shenzhen Eye HospitalShenzhen, ChinaNot yet recruiting
- Tianjin Medical University Eye HospitalTianjin, ChinaNot yet recruiting
- Tianjin Medical University General HospitalTianjin, ChinaTaking people
- The First Affiliated Hospital of Wenzhou Medical UniversityWenzhou, ChinaNot yet recruiting
- Tongji Hospital Tongji Medical College of HustWuhan, ChinaNot yet recruiting
- Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, ChinaNot yet recruiting
- Xi'an People's HospitalXi’an, ChinaNot yet recruiting
- Affiliated Hospital of Zunyi Medical UniversityZunyi, ChinaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Peking University People's Hospital
- Trial code
- NCT07640997
- Record updated
- 11 June 2026
- Original description
The goal of this observational study is to explore the effectiveness of aflibercept 8 mg in treating both treatment-naive and previously treated patients with neovascular age-related macular degeneration (nAMD) in a real-world setting. The main questions it aims to answer are:Read full original descriptionShow less
REFLECTION-An Observational Study Program to Investigate the Effectiveness of Aflibercept 8 mg Used in Neovascular Age-related Macular Degeneration (nAMD) in a Real-world Setting.
The goal of this observational study is to explore the effectiveness of aflibercept 8 mg in treating both treatment-naive and previously treated patients with neovascular age-related macular degeneration (nAMD) in a real-world setting. The main questions it aims to answer are:
What are the short-term and long-term efficacy outcomes of aflibercept 8 mg in treatment-naive or previously treated nAMD patients? What are the safety characteristics and the treatment patterns of aflibercept 8 mg in these patient populations?
Participants will:
Receive aflibercept 8 mg as part of their clinical treatment for nAMD. Undergo assessments to evaluate both the efficacy and safety of the treatment over the short and long term.
Provide data on their visual acuity (BCVA) changes at multiple follow-up points (4 weeks, 8 weeks, 16 weeks, 6 months, and 12 months).
Report any adverse events and treatment patterns during the study period. Have their central subfield thickness (CST) measured at specified intervals. This study will help inform clinical practices regarding the use of aflibercept in nAMD patients and contribute to understanding its effectiveness and safety in real-world settings.
Inclusion: Patient aged ≥50 years; A diagnosis of nAMD; Signed informed patient consent before the start of data collection; Patients for whom the decision to initiate treatment with IVT aflibercept 8 mg according to a local product information was made as part of routine clinical practice.
Exclusion: The fellow eye has received intravitreal anti-VEGF treatment other than aflibercept within 28 days prior to enrollment; Additional exclusion criteria for naïve nAMD patients:; Any prior ocular treatment in the study eye or systemic treatment for nAMD; Additional exclusion criteria for pretreated nAMD patients:; Prior intravitreal anti-VEGF treatments in the study eye within the last 28 days; Prior treatment with intravitreal corticosteroid in the study eye within the last 3 months; Dexamethasone implant in the study eye within the last 6 months; Any concurrent drug releasing implant in the study eye; Contraindications as listed in the intravitreal aflibercept 8 mg local product information (Ocular or periocular infections, severe active intraocular inflammation, and known allergy to aflibercept or any of its excipients); Participation in an investigational program with interventions outside of clinical routine practice; Intraocular pressure (IOP) in the study eye > 25 mmHg.